Bonnetblanc J M, Royer C, Bedane C
Department of Dermatology, CHRU Dupuytren, Limoges, France.
Dermatology. 1996;193(4):321-3. doi: 10.1159/000246279.
Thalidomide is used for the symptomatic treatment of recurrent aphthous stomatitis (RAS). Some authors reported remissions, but this was not evaluated.
To evaluate the number of patients who could stop or reduce thalidomide treatment.
Twenty-five patients with RAS treated with thalidomide and followed during at least 1 year were retrospectively studied.
Six patients could stop the treatment and further presented minor aphthae, 10 needed minimal daily doses of thalidomide and 7 did not respond to 100 mg daily. One patient was not evaluated because of an early side effect and one was lost to follow-up.
This study showed that a minority of patients responded and could stop thalidomide therapy whereas another group of patients could be maintained in remission with low doses of thalidomide which may represent a means to reduce the potentially severe side effects.
沙利度胺用于复发性阿弗他口炎（RAS）的对症治疗。一些作者报道有缓解情况，但未进行评估。
评估能够停用或减少沙利度胺治疗的患者数量。
回顾性研究了25例接受沙利度胺治疗且至少随访1年的RAS患者。
6例患者能够停止治疗，之后出现轻度口疮；10例患者需要最小剂量的沙利度胺维持治疗，7例患者对每日100毫克剂量无反应。1例患者因早期副作用未进行评估，1例患者失访。
本研究表明，少数患者有反应并可停用沙利度胺治疗，而另一组患者可通过低剂量沙利度胺维持缓解，这可能是减少潜在严重副作用的一种方法。
Zotero 插件